Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)

PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
March 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus

PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
March 20, 2015 09:28 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014

PHILADELPHIA, March 20, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the year ended December 31, 2014. The net loss (including non-cash effects) was...
March 09, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand

PHILADELPHIA, March 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
March 02, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology

PHILADELPHIA, March 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced today that its manufacturing site located in New Brunswick, New...
February 23, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) as a "Systemic Exertion Intolerance Disease" (SEID)

PHILADELPHIA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced today that a new report, issued February 10, 2015 by the Institute of...
February 12, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses

Ampligen® May Be an Important Candidate for EBOV Testing in West Africa PHILADELPHIA, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or...
February 09, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo

PHILADELPHIA, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Based upon numerous Hemispherx stockholder requests, Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") has posted the report and...
February 02, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study

PHILADELPHIA, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the results of a new efficacy study of Ampligen® in a...
January 26, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments

PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...